{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:12:24Z","timestamp":1791364344412,"version":"4.3.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1016\/j.pnpbp.2006.02.001","type":"journal-article","created":{"date-parts":[[2006,3,30]],"date-time":"2006-03-30T12:52:14Z","timestamp":1143723134000},"page":"714-717","source":"Crossref","is-referenced-by-count":49,"title":["Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: A pilot study"],"prefix":"10.1016","volume":"30","author":[{"given":"Bun-Hee","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Ku","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun-Hwa","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2006.02.001_bib1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.brainres.2003.09.082","article-title":"The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release","volume":"1003","author":"Aihara","year":"2004","journal-title":"Brain Res"},{"key":"10.1016\/j.pnpbp.2006.02.001_bib2","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.4088\/JCP.v65n0918f","article-title":"Successful switch to aripiprazole after induction of hyperprolactinemia by ziprasidone: a case report","volume":"65","author":"Anghelescu","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.02.001_bib3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.0031-5990.2005.00001.x","article-title":"The art of prescribing. Principles of switching novel antipsychotic medications","volume":"41","author":"Antai-Otong","year":"2005","journal-title":"Perspect Psychiatr Care"},{"key":"10.1016\/j.pnpbp.2006.02.001_bib4","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors","volume":"302","author":"Burris","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pnpbp.2006.02.001_bib5","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00213-002-1344-3","article-title":"Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study","volume":"166","author":"Casey","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pnpbp.2006.02.001_bib6","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0149-2918(00)80086-7","article-title":"The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia","volume":"22","author":"David","year":"2000","journal-title":"Clin Ther"},{"key":"10.1016\/j.pnpbp.2006.02.001_bib7","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1517\/14656566.3.10.1381","article-title":"Antipsychotics: impact on prolactin levels","volume":"3","author":"Goodnick","year":"2002","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.pnpbp.2006.02.001_bib8","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/archpsyc.60.10.974","article-title":"Mechanism of new antipsychotic medications: occupancy is not just antagonism","volume":"60","author":"Grunder","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.02.001_bib9","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","article-title":"Antispychotic-induced hyperprolactinemia: mechanism, clinical features and management","volume":"64","author":"Haddad","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.pnpbp.2006.02.001_bib10","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0169-328X(98)00009-6","article-title":"Differential effects on D2 dopamine receptor and prolactin gene expression by haloperidol and aripiprazole in the rat pituitary","volume":"55","author":"Inoue","year":"1998","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.pnpbp.2006.02.001_bib11","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0028-3908(96)00100-1","article-title":"Dopamine receptors and brain function","volume":"35","author":"Jaber","year":"1996","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2006.02.001_bib12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0014-2999(02)01532-7","article-title":"The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor","volume":"441","author":"Jordan","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pnpbp.2006.02.001_bib13","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1124\/jpet.102.035303","article-title":"The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood\u2013brain disposition: a pharmacological analysis in rats","volume":"302","author":"Kapur","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pnpbp.2006.02.001_bib14","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pnpbp.2006.02.001_bib15","first-page":"329","article-title":"7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity","volume":"274","author":"Kikuchi","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pnpbp.2006.02.001_bib16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4088\/JCP.v60n0509","article-title":"Risperidone and associated amenorrhea: a report of 5 cases","volume":"60","author":"Kim","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.02.001_bib17","first-page":"419","article-title":"Hyperprolactinemia after low dose of amisulpride","volume":"25","author":"Kopecek","year":"2004","journal-title":"Neuro Endocrinol Lett"},{"key":"10.1016\/j.pnpbp.2006.02.001_bib18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/13651500510014747","article-title":"Treatment in risperidone-induced amenorrhea","volume":"9","author":"Lee","year":"2005","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.pnpbp.2006.02.001_bib19","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1176\/appi.ajp.161.10.1925","article-title":"Prolactin elevation with ziprasidone","volume":"161","author":"Lusskin","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.02.001_bib20","first-page":"56","article-title":"Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences","volume":"63","author":"Maguire","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.02.001_bib21","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2165\/00023210-200216110-00008","article-title":"Aripiprazole","volume":"16","author":"McGavin","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pnpbp.2006.02.001_bib22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/ajmg.1303","article-title":"Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol","volume":"105","author":"Mihara","year":"2001","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.pnpbp.2006.02.001_bib23","first-page":"839","article-title":"Clinical global impression scale","volume":"4","author":"National Institute of Mental Health","year":"1985","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.pnpbp.2006.02.001_bib24","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","article-title":"Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder","volume":"60","author":"Potkin","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.02.001_bib25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00004850-200401000-00009","article-title":"Aripiprazole possibly worsens psychosis","volume":"19","author":"Ramaswamy","year":"2004","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2006.02.001_bib26","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1176\/appi.ajp.161.7.1308","article-title":"Worsening schizoaffective disorder with aripiprazole","volume":"161","author":"Reeves","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.02.001_bib27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.schres.2005.01.009","article-title":"The crossover approach to switching antipsychotics: what is the evidence?","volume":"76","author":"Remington","year":"2005","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2006.02.001_bib28","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1176\/appi.ajp.162.8.1542-a","article-title":"Reversal of symptomatic hyperprolactinemia by aripiprazole","volume":"162","author":"Wahl","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.02.001_bib29","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1192\/bjp.185.2.147","article-title":"Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2\u204eA1 allele","volume":"185","author":"Young","year":"2004","journal-title":"Br J Psychiatry"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584606000352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584606000352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T11:00:11Z","timestamp":1547722811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584606000352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["S0278584606000352"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2006.02.001","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}